Compositions and methods for the treatment of myotonic dystrophy

A genome and repetitive sequence technology, applied in the field of compositions for the treatment of myotonic dystrophy, can solve the problems of unsuitable removal of trinucleotide repeat sequence expansion regions and the like

Pending Publication Date: 2019-10-15
GENETHON +1
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the latter is considered by those skilled in the art to be unsuitable for excision of trinucleotide repeat expansions (see Richard cited above)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for the treatment of myotonic dystrophy
  • Compositions and methods for the treatment of myotonic dystrophy
  • Compositions and methods for the treatment of myotonic dystrophy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0138] A table matching the SEQ ID NOs to the sgRNA numbers used in the experimental section and figures below is provided below.

[0139] sgRNA ID 1 4 7 8B 12 12B SEQ ID NO 1 20 3 4 21 6

[0140] Materials and methods

[0141] Plasmid construction

[0142] The plasmid encoding S. aureus Cas9 was derived from the plasmid pX601-AAV-CMV::NLS-SaCas9-NLS-3xHA-bGHpA;U6::BsaI-sgRNA(MLS42) [Ran et al., 2015]. The EFS promoter was PCR amplified with primers F-XhoI-MreI-EFS (MLS63) and R-XmaI-NruI-EFS (MLS64) and cloned into the promoterless pX601-AAV-::NLS-SaCas9- NLS-3xHA-bGHpA;U6::BsaI-sgRNA XhoI / AgeI sites to obtain pAAV-EFS::NLS-SaCas9-NLS-3xHA-bGHpA;U6::BsaI-sgRNA(MLS43).

[0143] The second sgRNA cassette (U6::BbsI-sgRNA) was cloned in tandem into the Acc65I site upstream of the first sgRNA cassette in plasmid MLS43 to obtain construct pAAV-EFS::NLS-SaCas9-NLS-3xHA-bGHpA; U6::BbsI-sgRNA; U6::BsaI-sgRNA (MLS47). Insert U6::BbsI-sgRNA was synt...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to compositions and methods for the treatment of myotonic dystrophy.

Description

technical field [0001] The present invention relates to compositions and methods for treating myotonic dystrophy. Background technique [0002] Nucleotide repeat expansions, especially trinucleotide repeat expansions, have been implicated in more than twenty neurological and developmental disorders. One approach to treating these diseases has been proposed to use highly specific nucleases to shorten repeat sequences to nonpathological lengths (see review by Richard GF, Trends Genet. 2015 Apr;31(4):177-186). [0003] Highly specific nucleases such as meganucleases, ZFNs, TALENs and CRISPR-Cas9 nucleases have been used in such strategies. However, those skilled in the art consider the latter to be unsuitable for excision of trinucleotide repeat expansions (see Richard cited above). In conclusion, TALENs are considered to be more promising tools for shortening trinucleotide repeats. [0004] Against this strong bias, the inventors here show that a CRISPR-Cas9 system can be i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/113C12N9/22C12N15/63C12N15/90A61P21/00C12N15/11
CPCC12N9/22C12N15/113C12N15/907C12N2310/10C12N2310/20C12N15/90C12N2750/14141A61P21/00A61P21/04A61P43/00A61K9/0019A61K35/12C12N15/86
Inventor 安娜·玛利亚·布吉贝洛米雷拉·洛斯克鲁达托
Owner GENETHON
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap